MedXCell SA

The core activity of MedXCell is to identify scientific breakthroughs and convert them into clinical assets. To achieve this, the company develops early-stage projects in collaboration with academic institutions, establishes independent companies to commercialize the most promising ideas, and finances and manages their operations before integrating co-investors for later development. The focus is on developing technologies, techniques or new applications for major diseases such as cancer, autoimmune diseases, neurological and degenerative disorders.